These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2723131)

  • 1. Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety.
    Tollefson GD; Godes M; Montague-Clouse J; Lancaster SP; Garvey MJ
    J Clin Psychopharmacol; 1989 Apr; 9(2):132-6. PubMed ID: 2723131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety.
    Tollefson GD
    J Clin Psychopharmacol; 1989 Oct; 9(5):387. PubMed ID: 2794103
    [No Abstract]   [Full Text] [Related]  

  • 3. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls.
    Malt EA; Olafsson S; Aakvaag A; Lund A; Ursin H
    J Affect Disord; 2003 Jun; 75(1):77-82. PubMed ID: 12781354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin 1A receptor activation and hypothermia in humans: lack of evidence for a presynaptic mediation.
    Blier P; Seletti B; Gilbert F; Young SN; Benkelfat C
    Neuropsychopharmacology; 2002 Aug; 27(2):301-8. PubMed ID: 12093604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of buspirone on prolactin and growth hormone secretion in man.
    Meltzer HY; Flemming R; Robertson A
    Arch Gen Psychiatry; 1983 Oct; 40(10):1099-102. PubMed ID: 6138009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone).
    Tollefson GD; Montague-Clouse J; Tollefson SL
    J Clin Psychopharmacol; 1992 Feb; 12(1):19-26. PubMed ID: 1552035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine effects of buspirone in patients with generalized anxiety disorder.
    Cohn JB; Wilcox CS; Meltzer HY
    Am J Med; 1986 Mar; 80(3B):36-40. PubMed ID: 3963033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled comparison of buspirone and oxazepam in generalized anxiety.
    Ansseau M; Papart P; Gérard MA; von Frenckell R; Franck G
    Neuropsychobiology; 1990-1991; 24(2):74-8. PubMed ID: 2134114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I have heard that buspirone regularly affects various blood tests. Is this so?
    Shader RI
    J Clin Psychopharmacol; 1996 Apr; 16(2):194. PubMed ID: 8690840
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolactin response to buspirone is not impaired in drug-naïve first episode patients with major depressive disorder.
    Cubała WJ; Landowski J
    J Affect Disord; 2014 Jan; 152-154():468-73. PubMed ID: 24035672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prolactin response to buspirone in chronic fatigue syndrome.
    Sharpe M; Clements A; Hawton K; Young AH; Sargent P; Cowen PJ
    J Affect Disord; 1996 Nov; 41(1):71-6. PubMed ID: 8938208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
    Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
    Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin response to buspirone challenge in the presence of dopaminergic blockade.
    Maskall DD; Zis AP; Lam RW; Clark CM; Kuan AJ
    Biol Psychiatry; 1995 Aug; 38(4):235-9. PubMed ID: 8547445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central 5-HT receptor hypersensitivity in migraine without aura.
    Cassidy EM; Tomkins E; Dinan T; Hardiman O; O'Keane V
    Cephalalgia; 2003 Feb; 23(1):29-34. PubMed ID: 12534577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy.
    Goldberg HL
    Pharmacotherapy; 1984; 4(6):315-24. PubMed ID: 6151170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man.
    Meltzer HY; Fleming R
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):76-9. PubMed ID: 6130077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man.
    Grasby PM; Friston KJ; Bench C; Cowen PJ; Frith CD; Liddle PF; Frackowiak RS; Dolan RJ
    Psychopharmacology (Berl); 1992; 108(3):380-6. PubMed ID: 1523287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.
    Shim JC; Kim YH; Kelly DL; Lee JG; Conley RR
    J Neuropsychiatry Clin Neurosci; 2005; 17(2):221-6. PubMed ID: 15939977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone.
    Cowen PJ; Power AC; Ware CJ; Anderson IM
    Br J Psychiatry; 1994 Mar; 164(3):372-9. PubMed ID: 8199791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers.
    Anderson IM; Cowen PJ
    Psychopharmacology (Berl); 1992; 106(3):428-32. PubMed ID: 1570392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.